Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd. is a dermatology company based in Israel that develops innovative topical skin medications. The company was founded in 1997 by Dr. Alon Seri-Levy and Prof. David Avnir, who pioneered the use of sol-gel technology for drug delivery. Sol-Gel's headquarters are located in Nes Ziona, a city in central Israel. As of May 2023, the company has a market cap of $108.7M.

Sol-Gel's vision is to improve the lives of patients with skin diseases by providing them with effective and safe treatments that are based on its proprietary sol-gel technology. Sol-gel technology allows the encapsulation of active ingredients in silica-based microcapsules, which can enhance their stability, bioavailability, and penetration into the skin.

Sol-Gel has two FDA-approved products that are marketed by Galderma in the US since 2022: Twyneo® and Epsolay®. Twyneo® is a combination of benzoyl peroxide and tretinoin for the treatment of acne vulgaris, and Epsolay® is a microencapsulated benzoyl peroxide cream for the treatment of inflammatory lesions of rosacea. Both products have demonstrated superior efficacy and safety compared to their respective monotherapies in clinical trials.

In 2021, Sol-Gel received the Frost & Sullivan Technology Innovation Leadership Award for its achievements in the dermatology market. The award recognizes Sol-Gel's excellence in innovation, customer value, and market impact.

Foundation: 1997
Headquarters: Nes Ziona, Israel
Website: https://www.sol-gel.com/